Plenary Session - inactive due to federal service

This week's episode is on nutritional epidemiology by JPA Ioannidis; lenvatinib for hepatocellular carcinoma; nivolumab and ipilimumab for melanoma; and #medtwitter with Dr. Avi O Glasser from OHSU.

We're moving to our new format. We begin with a monologue of the most noteworthy articles in this week's news. We'll be talking about real-world evidence, Right to Try, talazoparib, and the FDA approval for nivolumab in small-cell lung cancer. In the second half of the show, we'll interview Dr. Andrae Vandross, a community oncologist at UCLA Medical Center.

In episode 2, we discuss the fellowship program and then take a deep dive into hype surrounding cancer drugs. Our guest is Jeremy Cetnar, MD from Oregon Health & Science University.

Join us for an introduction to who we are and what our podcast is about, then stick around for a hard-hitting discussion of evidence-based medicine, randomized controlled trials, sham controls, and broad next-generation sequencing in cancer. Our guest is Adam Obley, an Assistant Professor of Medicine at Oregon Health & Science University.